drugset
drugset / Trial / NCT02443337

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

NCT02443337 ↗

Phase 2 Terminated 31 enrolled Eli Lilly and Company SCRI Development Innovations, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).

Timeline

Start
2015-07
Primary completion
2017-09
Completion
2017-09

Outcome

Outcome not reported

Stopped: “The study stopped due to lack of efficacy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Necitumumab Monoclonal antibody 800 mg Intravenous
Subject Samotolisib Small molecule 200 mg Oral

Indications

non-small cell lung carcinoma